• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CSF 神经丝轻链和胶质纤维酸性蛋白的联合检测可改善多发性硬化症长期确诊残疾恶化的预测。

The combination of CSF neurofilament light chain and glial fibrillary acidic protein improves the prediction of long-term confirmed disability worsening in multiple sclerosis.

机构信息

Neurology, The Ottawa Hospital, 501 Smyth Road, Room 4118, Ottawa, ON, K1H 8L6, Canada.

Neurology, University of Pennsylvania, Philadelphia, United States.

出版信息

Sci Rep. 2024 Nov 25;14(1):29135. doi: 10.1038/s41598-024-75290-8.

DOI:10.1038/s41598-024-75290-8
PMID:39587121
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11589836/
Abstract

Our objective was to evaluate the individual and combined prognostic attributes of baseline serum and CSF measurements of Neurofilament light chain (sNfL, cNfL) and glial fibrillary acidic protein (sGFAP, cGFAP) on long term clinical outcomes in MS. In this retrospective single center study, patients with serum and CSF stored at first MS presentation and > 15-years of follow-up were analyzed. NfL and GFAP were quantified from cryopreserved samples using a digital immunoassay and analyzed as predictors of confirmed disability worsening (CDW). Sixty patients (70% female) underwent baseline tandem CSF and serum sampling and were followed for a mean of 17.8 years (SD 2.5). 32 developed CDW. By logistic regression, while sNfL cNfL and cGFAP showed prognostic merit (AUC 0.72, 0.70, 0.62 respectively), sGFAP did not (AUC 0.5). The combination of cNfL and cGFAP improved CDW prediction compared to either measure considered in isolation (AUC 0.72). The optimal predictive cut-off for CDW (Youden's index) for cNfL was 596 pg/mL and for cGFAP was 8160 pg/mL. Kaplan-Meier analysis of the cutoff-defined 'high-high' and 'low-low' combined cNfL and cGFAP groupings improved prediction of CDW compared to either marker individually (Hazard ratio 4.5 (95% CI 2.7-18.3), Logrank P < 0.0001). Cox Proportional Hazards regression demonstrated that high baseline cNfL and cGFAP were independently prognostic of subsequent CDW after adjusting for baseline age, sex, EDSS score and subsequent treatment exposure. Each unit increase in Ln(cNfL) and Ln(cGFAP) was respectively associated with an additional hazard of 2.36 (95% CI 1.12-5.52) and 2.26 (95% CI 1.03-5.21). CSF NfL and GFAP are independently prognostic of long-term clinical worsening in MS, and may represent a complementary pairing.

摘要

我们的目的是评估基线血清和脑脊液中神经丝轻链(sNfL、cNfL)和胶质纤维酸性蛋白(sGFAP、cGFAP)的个体和联合预后属性,以预测 MS 的长期临床结局。在这项回顾性单中心研究中,分析了首次 MS 发作时储存的血清和脑脊液,并随访了>15 年。使用数字免疫测定法从冷冻保存的样本中定量测定 NfL 和 GFAP,并将其分析为确认残疾进展(CDW)的预测因子。60 名患者(70%为女性)接受了基线串联 CSF 和血清取样,并平均随访 17.8 年(SD 2.5)。32 例发生 CDW。通过逻辑回归,sNfL、cNfL 和 cGFAP 具有预后价值(AUC 分别为 0.72、0.70 和 0.62),而 sGFAP 则没有(AUC 为 0.5)。与单独考虑任何一项测量相比,cNfL 和 cGFAP 的组合可改善 CDW 的预测(AUC 为 0.72)。用于 CDW 的最佳预测截断值(Youden 指数)为 cNfL 为 596pg/mL,cGFAP 为 8160pg/mL。根据截断值定义的“高-高”和“低-低”联合 cNfL 和 cGFAP 分组的 Kaplan-Meier 分析,与单独使用任何一种标志物相比,均可改善 CDW 的预测(风险比 4.5(95%CI 2.7-18.3),Logrank P<0.0001)。Cox 比例风险回归表明,在校正基线年龄、性别、EDSS 评分和随后的治疗暴露后,高基线 cNfL 和 cGFAP 与随后的 CDW 独立相关。Ln(cNfL)和 Ln(cGFAP)每增加一个单位,分别与 2.36(95%CI 1.12-5.52)和 2.26(95%CI 1.03-5.21)的额外风险相关。CSF NfL 和 GFAP 是 MS 长期临床恶化的独立预后因素,可能是互补配对。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d19a/11589836/a06e43e6bccd/41598_2024_75290_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d19a/11589836/011c26db3616/41598_2024_75290_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d19a/11589836/88452ee94b21/41598_2024_75290_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d19a/11589836/81451c8edd3f/41598_2024_75290_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d19a/11589836/4f9a39b6e3d5/41598_2024_75290_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d19a/11589836/a06e43e6bccd/41598_2024_75290_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d19a/11589836/011c26db3616/41598_2024_75290_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d19a/11589836/88452ee94b21/41598_2024_75290_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d19a/11589836/81451c8edd3f/41598_2024_75290_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d19a/11589836/4f9a39b6e3d5/41598_2024_75290_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d19a/11589836/a06e43e6bccd/41598_2024_75290_Fig5_HTML.jpg

相似文献

1
The combination of CSF neurofilament light chain and glial fibrillary acidic protein improves the prediction of long-term confirmed disability worsening in multiple sclerosis.CSF 神经丝轻链和胶质纤维酸性蛋白的联合检测可改善多发性硬化症长期确诊残疾恶化的预测。
Sci Rep. 2024 Nov 25;14(1):29135. doi: 10.1038/s41598-024-75290-8.
2
Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury.将侵袭性多发性硬化的临床和 MRI 拟议标准与神经轴突和神经胶质损伤的血清和脑脊液标志物相匹配。
J Neurol. 2024 Jun;271(6):3512-3526. doi: 10.1007/s00415-024-12299-z. Epub 2024 Mar 27.
3
Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study.血清神经丝轻链和胶质纤维酸性蛋白在水通道蛋白 4 免疫球蛋白 G 阳性视神经脊髓炎谱系疾病和多发性硬化中的作用:一项队列研究。
J Neurochem. 2021 Dec;159(5):913-922. doi: 10.1111/jnc.15478. Epub 2021 Jul 28.
4
Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.血清 GFAP 和神经丝轻链作为 NMOSD 疾病活动和残疾的生物标志物。
Neurology. 2019 Sep 24;93(13):e1299-e1311. doi: 10.1212/WNL.0000000000008160. Epub 2019 Aug 30.
5
Serum biomarkers at disease onset for personalized therapy in multiple sclerosis.用于多发性硬化症个性化治疗的疾病发作时血清生物标志物。
Brain. 2024 Dec 3;147(12):4084-4093. doi: 10.1093/brain/awae260.
6
GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients.神经毒性时 GFAP 和 NfL 从儿科 CD19-CAR T 细胞患者的高基线水平增加。
Blood Adv. 2023 Mar 28;7(6):1001-1010. doi: 10.1182/bloodadvances.2022008119.
7
Evaluating the utility of serum NfL, GFAP, UCHL1 and tTAU as estimates of CSF levels and diagnostic instrument in neuroinflammation and multiple sclerosis.评估血清 NfL、GFAP、UCHL1 和 tTAU 作为神经炎症和多发性硬化症中 CSF 水平和诊断工具的估计值的效用。
Mult Scler Relat Disord. 2024 Jul;87:105644. doi: 10.1016/j.msard.2024.105644. Epub 2024 Apr 26.
8
Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis.血清神经丝轻链与胶质纤维酸性蛋白作为多发性硬化症疾病进展的生物标志物比较。
JAMA Neurol. 2023 Mar 1;80(3):287-297. doi: 10.1001/jamaneurol.2022.5250.
9
Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes.早期神经丝轻链和胶质纤维酸性蛋白水平提高多发性硬化结局预测模型。
Mult Scler Relat Disord. 2023 Jun;74:104695. doi: 10.1016/j.msard.2023.104695. Epub 2023 Apr 2.
10
Effect of Estimated Blood Volume and Body Mass Index on GFAP and NfL Levels in the Serum and CSF of Patients With Multiple Sclerosis.估算血容量和体重指数对多发性硬化症患者血清和脑脊液中 GFAP 和 NfL 水平的影响。
Neurol Neuroimmunol Neuroinflamm. 2022 Oct 31;10(1). doi: 10.1212/NXI.0000000000200045. Print 2023 Jan.

引用本文的文献

1
Clinical application of age-derived cut-offs for plasma neurofilament light chain in multiple sclerosis.年龄衍生的血浆神经丝轻链临界值在多发性硬化症中的临床应用
J Neurol. 2025 Jul 9;272(8):495. doi: 10.1007/s00415-025-13223-9.
2
Biomarkers of Progression Independent of Relapse Activity-Can We Actually Measure It Yet?独立于复发活动的疾病进展生物标志物——我们真的能够对其进行测量了吗?
Int J Mol Sci. 2025 May 14;26(10):4704. doi: 10.3390/ijms26104704.
3
Role of soluble biomarkers in treating multiple sclerosis and neuroinflammatory conditions.
可溶性生物标志物在治疗多发性硬化症和神经炎症性疾病中的作用。
Neurotherapeutics. 2025 Jul;22(4):e00588. doi: 10.1016/j.neurot.2025.e00588. Epub 2025 Apr 19.